SEC For	m 4																			
	FORM	4	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549														OMB APPROVAL			
Section obligat	this box if no k n 16. Form 4 or ions may conti tion 1(b).	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934												Estimated average burden			3235-0287 n 0.5			
									Investment											
1. Name and Address of Reporting Person [*] Musso Alan A									ker or Tradin eutics, In				elationship o eck all applica Director	able) -	g Pers	10% O	wner			
(Last)	(F	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 01/26/2024								X Officer (give title Other (spec below) below) Chief Financial Officer			specify				
C/O FULCRUM THERAPEUTICS, INC. 26 LANDSDOWNE STREET					4.	Line))	vidual or Joint/Group Filing (Check Applicable						
(Street) CAMBR	Street) CAMBRIDGE MA 02139														Form filed by More than One Reporting Person					
(City) (State) (Zip)					Rule 10b5-1(c) Transaction Indication															
		Ta	ble I - Nor	-Doriv		the a	affirmative o	defens	se conditions o	of Ru	le 10b5-1(c	c). See Instru	uction 10.		or written p					
Table I - Non-Deriv 1. Title of Security (Instr. 3) 2. Trans Date (Month/l)				actio				3. Transact Code (In	3. 4. S Transaction Disp Code (Instr.		curities Acquired (A) osed Of (D) (Instr. 3, 4) or 4 and 5) Beneficia Owned Fo		Form (D) or	/nership : Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership			
									Code	v	Amount	(A) o (D)	r Price	Reported Transaction(s (Instr. 3 and 4				(Instr. 4)		
			Table II -	Deriva (e.g., p	tive outs	e Sec , cal	urities Is, warr	Acq ants	uired, Dis s, options	spo s, co	osed of, onverti	, or Ben ble secu	eficially urities)	Owned						
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Da if any (Month/Day/ [*]	ate, Tr Co	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exer Expiration E (Month/Day	Date		d 7. Title and Am of Securities Underlying Derivative Secu (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				C	ode	v	(A)	A) (D) Ex			xpiration ate	Title	Amount or Number of Shares		(Instr. 4)					
Stock Option (right to buy)	\$6.95	01/26/2024			A		100,000		(1)	01	1/25/2034	Common Stock	100,000	\$0.00	100,0	00	D			

Explanation of Responses:

1. This option was granted on January 26, 2024 and is scheduled to vest in equal quarterly installments over four years beginning on the vesting commencement date of January 1, 2024, subject to the reporting person's continued service on each such vesting date.

/s/ Alan Musso

** Signature of Reporting Person

01/30/2024

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.